Pharnext Announces Preclinical Trial Results Affecting Onset of Charcot-Marie-Tooth Disease 1A
source: pixabay.com

Pharnext Announces Preclinical Trial Results Affecting Onset of Charcot-Marie-Tooth Disease 1A

Pharnext SA, a biopharmaceutical company, recently announced results in a PLOS ONE article entitled "Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A…

Continue Reading Pharnext Announces Preclinical Trial Results Affecting Onset of Charcot-Marie-Tooth Disease 1A